Troy– Author –
-
Kyoto University iPSC Research Foundation Opens ‘Yanai my iPS Manufacturing Facility’ to Massively Enhance Clinical-Grade Autologous iPSC Production in Japan
BigGo Finance Japan Overview In 2025, with a substantial investment from Uniqlo founder Tadashi Yanai, the Kyoto University iPSC Research Foundation officially opened the 'Yanai my iPS Manufacturing Facility.' This marks Japan's first cl... -
Chinese Scientists Achieve Breakthrough: Mass Production of 14 Million NK Immune Cells from a Single Stem Cell, Paving Way for ‘Off-the-Shelf’ Immunotherapy
Facebook (referencing a February 2026 breakthrough in China) China Overview In February 2026, Chinese scientists announced a breakthrough, successfully mass-producing an astounding 14 million natural killer (NK) immune cells in the lab f... -
Hopstem Biotech Closes ~RMB 200M Series C Funding to Accelerate Development of FDA RMAT-Designated iPSC Cell Therapy hNPC01
Insight, China's Pharmaceutical Industry China Overview Hopstem Biotechnology announced the first close of its Series C funding round, raising approximately RMB 200 million (~$40 million USD). This capital will accelerate clinical develo... -
INFORMA Database Analysis Reveals Rapid Growth of Allogeneic NK Cell Immunotherapy, CAR-Engineered NK Cells Transitioning to Standardized Platforms
INFORMA database (journal article) International Overview Natural killer (NK) cell-based immunotherapy is gaining increasing prominence as a cancer treatment strategy due to its inherent cytotoxicity, allogeneic potential, and compatibil... -
Liv Hospital Charts Course for Scalable CAR-T Production with Comprehensive GMP and Bioreactor Guide
Liv Hospital Turkey Overview Liv Hospital has released a comprehensive guide detailing the critical, GMP-compliant manufacturing process for CAR-T cell therapies, from T-cell collection and genetic modification to controlled expansion in... -
AstraZeneca Accelerates Next-Gen Cell Therapy Manufacturing: Gracell’s Rapid Platform Reduces Autologous CAR T Production Time
AstraZeneca UK Overview AstraZeneca is addressing critical challenges in cell therapy by accelerating autologous cell therapy manufacturing and advancing allogeneic and in vivo 'off-the-shelf' approaches. Notably, they are leveraging Gra... -
Liv Hospital Details Advanced ‘Off-the-Shelf’ CAR-T Manufacturing, Promising Scalability and Broader Access
Liv Hospital Turkey Overview Liv Hospital has unveiled its detailed manufacturing process for allogeneic, 'off-the-shelf' CAR-T cell therapy, a significant leap towards overcoming the logistical and cost barriers of current personalized ... -
Closed, Automated Culture Systems Critical for iPSC Therapy Manufacturing to Ensure GMP and Scalability
Contract Pharma USA Overview iPSC-derived cell therapies are rapidly emerging as scalable solutions across regenerative medicine and oncology, yet ensuring GMP-grade production and consistency across large-scale manufacturing platforms r... -
NueCell Bio Unveils 26,300 Sq Ft Cell Therapy Development Facility in San Diego, Bolstering Clinical & Commercial Manufacturing
PharmaSource USA Overview NueCell Bio has officially opened its 26,300-square-foot cell therapy development facility in San Diego, significantly enhancing its clinical and commercial manufacturing capabilities. The state-of-the-art facil... -
Biopharmaceutical CDMO Capacity Crunch Persists, Driving Rapid Expansion in Cell and Gene Therapy Production
Contract Pharma USA Overview The biopharmaceutical industry continues to face a CDMO capacity crunch, prompting contract development and manufacturing organizations to heavily invest in expanding production capabilities, particularly for...
